EUVIMEDEUVIMED entdecken
Crossref

Real Life Switching from Infliximab Innovator to Biosimilar in Rheumatic Diseases: A 6-Month Single-Centre Prospective Observational Study

Aqeel M Anjum, Ng WL, Sebastian A, Devlin J, Fraser A

Fortune Journal of Rheumatology · 2019

DOI: 10.26502/fjr.26880011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fortune Journal of Rheumatology, 2019. Verfasst von Aqeel M Anjum und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although Inflectra, biosimilar infliximab, has been approved by the EMA since September 2013 for all licensed indications of Remicade (innovator infliximab) but there is a paucity of real-world data and guidelines regarding switching from innovator Remicade to Inflectra.

Objectives

To explore efficacy, safety, and retention rate of biosimilar Inflectra when switching from Remicade, in patients with rheumatic diseases.

Methods

Informed consent was sought from all patients attending our rheumatology unit to undertake a switching programme. Baseline demographics and clinical characteristics were obtained before switching to Inflectra. Disease activity and safety assessment were undertaken before and then every 12 weeks after switching. The retention rate of Inflectra switch patients was compared with a cohort of non-switch Inflectra naive (11 patients) and historic Remicade (31 patients) patients.

Results

Thirty out of thirty-one patients {median (IQR) age 50 (18), 20F} with various rheumatic diseases (9 with diagnosis of AS, 6 with RA, 6 with Behçet’s disease, 3 with Enteropathic arthritis, 2 with psoriatic arthritis) agreed to the switch. There was no statistical difference noted between pre-switch and 6 months post-switch mean values of PGA (p=0.37), BASDAI (p=0.60), ASDAS-CRP (p=0.90), DAS28CRP (p=0.85), DAS28ESR (p=0.45), CRP (p=0.09), Behçet’s disease activity score (p=0.77) and HAQ-DI (p=0.18). The retention rate on Inflectra switch was 86.7% as compared to 90.9% in the Inflectra naive cohort and 100% for historic Remicade cohort.

Conclusion

These results demonstrate that in this cohort at 6 months Inflectra is comparable to Remicade in efficacy and there are no new safety signals.

Zitieren

APA

Anjum, A. M., WL, N., A, S., J, D., & A, F. (2019). Real Life Switching from Infliximab Innovator to Biosimilar in Rheumatic Diseases: A 6-Month Single-Centre Prospective Observational Study. Fortune Journal of Rheumatology. https://doi.org/10.26502/fjr.26880011

Vancouver

Anjum AM, WL N, A S, J D, A F. Real Life Switching from Infliximab Innovator to Biosimilar in Rheumatic Diseases: A 6-Month Single-Centre Prospective Observational Study. Fortune Journal of Rheumatology. 2019. doi:10.26502/fjr.26880011

BibTeX
@article{Anjum2019,
  author = {Anjum, Aqeel M and WL, Ng and A, Sebastian and J, Devlin and A, Fraser},
  title = {Real Life Switching from Infliximab Innovator to Biosimilar in Rheumatic Diseases: A 6-Month Single-Centre Prospective Observational Study},
  journal = {Fortune Journal of Rheumatology},
  year = {2019},
  doi = {10.26502/fjr.26880011}
}
Kostenlos starten →